PubHawk
BMC Cancer April 2023 PMID 37061680

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.

Dilara Akhoundova Sanoyan, Katja Seipel, Ulrike Bacher, Marie-Noelle Kronig, Naomi Porret, Gertrud Wiedemann, Michael Daskalakis, Thomas Pabst

Full text PDF Download social card

Mentions

3
Peak: 1 in Apr 2023
across 2 sources since Apr 2023

Extended reach

9,834
potential audience

Total likes

2

Video views

36

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

  • X / Twitter2 posts
  • YouTube1 videos

AI synopsis

What people are saying

Discussions highlight key statistics from the publication, such as the 69% overall response rate and side effects like cytokine release syndrome and prolonged hematologic toxicity, with tone indicating cautious optimism and acknowledgment of the therapy's potential benefits despite side effects. Words like 'high response', 'manageable safety', and mention of real-life experiences contribute to the perception of meaningful impact and interest.

AgreementModerate agreement

There is general support for the positive outcomes reported, especially the high response rate of 69%.

InterestHigh interest

The detailed data, such as percentages for side effects like CRS (94%) and prolonged hematologic toxicity (25%), demonstrate strong engagement and curiosity.

EngagementModerate engagement

Discussions reference specific treatment outcomes, including side effect rates and response durability, indicating moderate depth of involvement.

ImpactModerate impact

The focus on real-life data and potential predictors like CAR T-cell expansion suggest recognition of the therapy's significance in clinical settings.

Abstract in brief

  • This study reports on the real-life use of the CAR T-cell therapy idecabtagene vicleucel (idecel) in treating patients with relapsed/refractory multiple myeloma who have already received multiple prior treatments, showing a 69% overall response rate.
  • Most common side effects included cytokine release syndrome (94%), neurotoxicity (6%), and blood-related toxicity like febrile neutropenia, with some patients experiencing prolonged hematologic toxicity.
  • The effectiveness of the therapy was higher in patients with greater CAR T-cell expansion and decreasing soluble BCMA levels, indicating these factors could predict better responses, while safety remained manageable overall.
Read the full abstract

Top posts

Most liked on X and Bluesky
Multiple Myeloma Hub
@MM_Hub · X

KEY POINTS Outcomes after RW ide-cel treatment in triple exposed RRMM in Switzerland ▪️ At 3 months, ORR, CRS, ICANS, febrile neutropenia, and infections occurred in 69%, 94%, 6%, 69%, and 31%, respectively ▪️ Prolonged hematologic toxicity in 25% https://t.co/IaNZJa6sW4 #mmsm

May 13, 2023 · 2 likes · 9,551 followers View post →
ImmunotherapyPapers
@Immunotx_papers · X

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients https://t.co/FoZGRRlHie

Apr 17, 2023 · 247 followers View post →

All mentions

Multiple Myeloma Hub
@MM_Hub · X

KEY POINTS Outcomes after RW ide-cel treatment in triple exposed RRMM in Switzerland ▪️ At 3 months, ORR, CRS, ICANS, febrile neutropenia, and infections occurred in 69%, 94%, 6%, 69%, and 31%, respectively ▪️ Prolonged hematologic toxicity in 25% https://t.co/IaNZJa6sW4 #mmsm

May 13, 2023 · 2 likes · 9,551 followers View post →
ImmunotherapyPapers
@Immunotx_papers · X

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients https://t.co/FoZGRRlHie

Apr 17, 2023 · 247 followers View post →